Return to Medscape coverage of: American Society of Clinical Oncology 39th Annual Meeting

Print this Activity for Offline ReferenceInstructions on Taking Medscape CME
American Society of Clinical Oncology 39th Annual Meeting
Posters and Abstracts: Gynecologic Cancer
May 31, 2003 - June 3, 2003, Chicago, Illinois



This activity is not sanctioned by, nor a part of, the American Society of Clinical Oncology.


Contents

There are a number of considerations for treating ovarian cancer, from the chemotherapeutic approaches in first-line therapy, to the chemotherapeutic, intraperitoneal, neoadjuvant chemoradiation, or molecular targeted approach in second-line therapy. At the 39th Annual Meeting of the American Society of Clinical Oncology, several presentations focused on the many issues that arise in the treatment of ovarian cancer, including dosing, sequencing, and toxicity, as researchers seek to improve the prognosis of women with ovarian cancer.

  1. Treatment Approaches to Ovarian Cancer
    Franca Lebow, MA


 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape, and do not represent a publication of the American Society of Clinical Oncology. These materials and the related activity are not sanctioned by the American Society of Clinical Oncology or the commercial supporter of the conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of Medical Education Collaborative, Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity.
Copyright © 2003 Medscape.

 
Lilly, Aventis Oncology, Genentech Bio-Oncology, Genentech-BioOnc-IDEC, AstraZeneca, Sanofi-Sythelabo-Oncology

Related Resources
Clinical articles on this topic
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.